Observational Studies of Statins in Heart Failure with Preserved Systolic Function

1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383 1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902 Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401 Levine, 1995, Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms, N Engl J Med, 332, 512, 10.1056/NEJM199502233320807 Smith, 2006, AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute, Circulation, 113, 2363, 10.1161/CIRCULATIONAHA.106.174516 Hunt, 2005, Circulation, 112, e154, 10.1161/CIRCULATIONAHA.105.167586 Swedberg, 2005, Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology, Eur Heart J, 26, 1115, 10.1093/eurheartj/ehi204 Horwich, 2002, Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure, J Card Fail, 8, 216, 10.1054/jcaf.2002.0804216 Rauchhaus, 2003, The relationship between cholesterol and survival in patients with chronic heart failure, J Am Coll Cardiol, 42, 1933, 10.1016/j.jacc.2003.07.016 Afsarmanesh, 2006, Total cholesterol levels and mortality risk in nonischemic systolic heart failure, Am Heart J, 152, 1077, 10.1016/j.ahj.2006.06.015 Horwich, 2004, Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure, J Am Coll Cardiol, 43, 642, 10.1016/j.jacc.2003.07.049 Mozaffarian, 2004, Statin therapy is associated with lower mortality among patients with severe heart failure, Am J Cardiol, 93, 1124, 10.1016/j.amjcard.2004.01.039 Sola, 2005, Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure, J Card Fail, 11, 607, 10.1016/j.cardfail.2005.05.011 Anker, 2006, Statin use and survival in patients with chronic heart failure: results from two observational studies with 5200 patients, Int J Cardiol, 112, 234, 10.1016/j.ijcard.2006.03.057 Krum, 2007, Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT, Int J Cardiol, 119, 48, 10.1016/j.ijcard.2006.07.106 Owan, 2005, Epidemiology of diastolic heart failure, Prog Cardiovasc Dis, 47, 320, 10.1016/j.pcad.2005.02.010 Bhatia, 2006, Outcome of heart failure with preserved ejection fraction in a population-based study, N Engl J Med, 355, 260, 10.1056/NEJMoa051530 Owan, 2006, Trends in prevalence and outcome of heart failure with preserved ejection fraction, N Engl J Med, 355, 251, 10.1056/NEJMoa052256 Bursi, 2006, Systolic and diastolic heart failure in the community, JAMA, 296, 2209, 10.1001/jama.296.18.2209 Fukuta, 2005, Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report, Circulation, 112, 357, 10.1161/CIRCULATIONAHA.104.519876 Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines, Circulation, 110, 227, 10.1161/01.CIR.0000133317.49796.0E Roik, 2006, Impact of statin therapy on survival in patients with diastolic heart failure, Eur Heart J, 27, 23 Folkeringa, 2006, Statins associated with reduced mortality in patients admitted for congestive heart failure, J Card Fail, 12, 134, 10.1016/j.cardfail.2005.10.014 Go, 2006, Statin therapy and risks for death and hospitalization in chronic heart failure, JAMA, 296, 2105, 10.1001/jama.296.17.2105 Ray, 2005, Statin use and survival outcomes in elderly patients with heart failure, Arch Intern Med, 165, 62, 10.1001/archinte.165.1.62 Foody, 2006, Statins and mortality among elderly patients hospitalized with heart failure, Circulation, 113, 1086, 10.1161/CIRCULATIONAHA.105.591446 Senni, 1998, Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991, Circulation, 98, 2282, 10.1161/01.CIR.98.21.2282 Vasan, 1999, Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort, J Am Coll Cardiol, 33, 1948, 10.1016/S0735-1097(99)00118-7 Ahmed, 2007, Hospitalizations due to unstable angina pectoris in diastolic and systolic heart failure, Am J Cardiol, 99, 460, 10.1016/j.amjcard.2006.08.056 Collins, 2003, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial, Lancet, 361, 2005, 10.1016/S0140-6736(03)13636-7 Tonelli, 2003, Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency, Ann Intern Med, 138, 98, 10.7326/0003-4819-138-2-200301210-00010 Nishikawa, 2004, Statins induce the regression of left ventricular mass in patients with angina, Circ J, 68, 121, 10.1253/circj.68.121 Patel, 2001, Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy, Circulation, 104, 317, 10.1161/hc2801.094031 Indolfi, 2002, Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation, Circulation, 106, 2118, 10.1161/01.CIR.0000034047.70205.97 Zile, 2002, New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment, Circulation, 105, 1503, 10.1161/hc1202.105290 Aurigemma, 2004, Clinical practice: diastolic heart failure, N Engl J Med, 351, 1097, 10.1056/NEJMcp022709 Redfield, 2004, Understanding diastolic heart failure, N Engl J Med, 350, 1930, 10.1056/NEJMp048064 Borghi, 2002, Interactions between hypercholesterolemia and hypertension: implications for therapy, Curr Opin Nephrol Hypertens, 11, 489, 10.1097/00041552-200209000-00003 Glorioso, 1999, Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia, Hypertension, 34, 1281, 10.1161/01.HYP.34.6.1281 Ferrier, 2002, Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension, J Am Coll Cardiol, 39, 1020, 10.1016/S0735-1097(02)01717-5 Smilde, 2000, The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia, Eur J Clin Invest, 30, 473, 10.1046/j.1365-2362.2000.00654.x Davignon, 2004, Beneficial cardiovascular pleiotropic effects of statins, Circulation, 109, III39, 10.1161/01.CIR.0000131517.20177.5a Wilkinson, 2002, Nitric oxide regulates local arterial distensibility in vivo, Circulation, 105, 213, 10.1161/hc0202.101970 Landmesser, 2005, Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans, Circulation, 111, 2356, 10.1161/01.CIR.0000164260.82417.3F Farrar, 1980, Reduction in pulse wave velocity and improvement of aortic distensibility accompanying regression of atherosclerosis in the rhesus monkey, Circ Res, 47, 425, 10.1161/01.RES.47.3.425 Corti, 2002, Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging, Circulation, 106, 2884, 10.1161/01.CIR.0000041255.88750.F0 O'Rourke, 2001, Diastolic heart failure, diastolic left ventricular dysfunction and exercise intolerance, J Am Coll Cardiol, 38, 803, 10.1016/S0735-1097(01)01452-8 Kass, 2004, What mechanisms underlie diastolic dysfunction in heart failure?, Circ Res, 94, 1533, 10.1161/01.RES.0000129254.25507.d6 Bauersachs, 2001, Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction, Circulation, 104, 982, 10.1161/hc3401.095946 Hayashidani, 2002, Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction, Circulation, 105, 868, 10.1161/hc0702.104164 Zaca, 2007, Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure, J Am Coll Cardiol, 50, 551, 10.1016/j.jacc.2007.04.050 Saka, 2006, Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure, J Cardiovasc Pharmacol, 47, 770, 10.1097/01.fjc.0000211791.22411.0d Ichihara, 2006, Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure, Cardiovasc Res, 69, 726, 10.1016/j.cardiores.2005.08.001 Young-Xu, 2003, Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease, Am J Cardiol, 92, 1379, 10.1016/j.amjcard.2003.08.040 Siu, 2003, Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion, Am J Cardiol, 92, 1343, 10.1016/j.amjcard.2003.08.023 Patti, 2006, Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After Cardiac Surgery) study, Circulation, 114, 1455, 10.1161/CIRCULATIONAHA.106.621763 Humphries, 2007, Statin use and recurrence of atrial fibrillation after successful cardioversion, Am Heart J, 154, 908, 10.1016/j.ahj.2007.07.015 Mitchell, 2003, Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial, J Am Coll Cardiol, 42, 81, 10.1016/S0735-1097(03)00498-4 Vyas, 2006, Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II, J Am Coll Cardiol, 47, 769, 10.1016/j.jacc.2005.09.053 Goldberger, 2006, Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy, J Am Coll Cardiol, 48, 1228, 10.1016/j.jacc.2006.05.053 Dickinson, 2007, Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), Am Heart J, 153, 573, 10.1016/j.ahj.2007.02.002 Deswal, 2001, Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST), Circulation, 103, 2055, 10.1161/01.CIR.103.16.2055 Rauchhaus, 2000, Plasma cytokine parameters and mortality in patients with chronic heart failure, Circulation, 102, 3060, 10.1161/01.CIR.102.25.3060 Givertz, 1998, New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress, Lancet, 352, SI34, 10.1016/S0140-6736(98)90017-4 Olsson, 2006, Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and Morbidity (CHARM) program, J Am Coll Cardiol, 47, 1997, 10.1016/j.jacc.2006.01.060 Solomon, 2004, Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity (CHARM) program, Circulation, 110, 2180, 10.1161/01.CIR.0000144474.65922.AA Solomon, 2005, Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients, Circulation, 112, 3738, 10.1161/CIRCULATIONAHA.105.561423 Rauchhaus, 2000, The endotoxin-lipoprotein hypothesis, Lancet, 356, 930, 10.1016/S0140-6736(00)02690-8 Zile, 2005, Treating diastolic heart failure with statins: phat chance for pleiotropic benefits, Circulation, 112, 300, 10.1161/CIRCULATIONAHA.105.551887 Kjekshus, 2005, A statin in the treatment of heart failure? Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA): study design and baseline characteristics, Eur J Heart Fail, 7, 1059, 10.1016/j.ejheart.2005.09.005 Tavazzi, 2004, Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure, Eur J Heart Fail, 6, 635, 10.1016/j.ejheart.2004.03.001 Kjekshus, 2007, Rosuvastatin in older patients with systolic heart failure, N Engl J Med, 357, 2248, 10.1056/NEJMoa0706201 Masoudi, 2007, Statins for ischemic systolic heart failure, N Engl J Med, 357, 2301, 10.1056/NEJMe0707221 Senni, 2001, Heart failure with preserved systolic function. A different natural history?, J Am Coll Cardiol, 38, 1277, 10.1016/S0735-1097(01)01567-4